Rajiv Sarman Shukla

Bharat Biotech International Ltd. engages in research and development, manufacturing, marketing and distribution of vaccines and biotherapeutics. It focuses on the development of novel health care solutions for region-specific neglected diseases. The firm offers Revac-B+, REGEN-D, HNVAC, COMVAC5, BIOPOLIO, INDIRAB, Typbar TCV, BIOHIB, JENVAC, ROTAVAC and vaccine candidates against chikungunya, chandipura, HPV and Ebola. The company was founded by Krishna Murthy Ella and Suchitra K. Ella in 1996 and is headquartered in Hyderabad, India..

Arch Pharmalabs Ltd. manufactures and sells pharmaceutical products. Its therapeutic segments include side chains of Semi-Synthetic Isoxazole Penicillins under Antibiotics, Lipid Lowering Agents, Oncology, Anti-Platelet Agents, Anti-Asthmatic, Anti-Retroviral, Decongestant, Anti-Herpes, Anti-Malarial, NSAIDs and Anti-Anginal segments. The company was founded in 1975 and is headquartered in Mumbai, India.

Malladi Drugs & Pharmaceuticals Ltd. manufactures active pharmaceutical ingredients. It manufactures Ephedrine and Pseudo-Ephedrine. The firm's products include active pharmaceutical ingredients, intermediates and speciality products,and chiral building blocks and speciality chemicals. Its services include contract manufacturing, custom synthesis and contract research. The company was founded by M. L. N. Satry in 1980 and is headquartered in Chennai, India.

ICICI Venture Funds Management Co. Ltd (ICICI) is a Private Equity firm, a subsidiary of ICICI Bank Ltd. founded in 1988. The firm is headquartered in India.

Avendus Capital Pvt Ltd. provides financial services. The firm offers financial advisory, mergers and acquisitions, private equity syndication, equity capital markets, structured finance, financial sponsors group, wealth management, alternative asset management, and institutional equities. The company was founded by Ranu Vohra, Gaurav Deepak and Kaushal Aggarwal and is headquartered in Mumbai, India.

Alpha Healthcare Acquisition Corp. operates as a blank check company, which is formed in order to effect a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination with one or more businesses or entities. The company was founded on July 1, 2020 and is headquartered in New York, NY.

OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA.

Alpha Healthcare Acquisition Corp. III is a blank check company, which engages in the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 21, 2021 and is headquartered in New York, NY.

Morgan Stanley Investment Management Pvt Ltd. (India) (MSIM), founded in 1993, is an asset management subsidiary of Morgan Stanley (NYSE: MS). The firm specializes in managing assets for a range of institutional clients, including endowments, foundations, pension funds, corporations, governments, and high-net worth individuals. The Mumbai office focuses on managing portfolios of Indian securities. MSIM has offices in New York, Philadelphia, Houston, Chicago, London, Tokyo, Amsterdam and Singapore.

InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy.